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Alzheimer's disease (AD) is a multisystem and multifactor disease with a long no-
symptom stage, hence likely not modeled by one or even a few models and very likely 
not be treated by a single drug. We propose that a more effective approach to use fMRI 
as a still emerging, repeatable and non- invasive neuroimaging tools that can be very 
useful for evaluating, diagnosis, treatment and drugs- development. 
Methods and Results: 
Factors of Alzheimer's disease (AD) is divided into two general types of genetic and 
non-genetic. We studied 30 articles which published between 2008-2017 that included 
the effects of different biomarkers and tools for diagnosing AD and assessing, 
improving and detection of Alzheimer's medications. Attractive alternatives to the 
animal and human experimental modeling approaches are the “multi-scale”and “multi-
level” computational modeling approaches to AD drug discovery and therapy. 6 articles 
(20%) were about the animal models while we should try accepting the limitations of 
animal models and focus more on humanize researches so we used it less considering, 
also as regard to the long waiting queue in AD drug development that we feel crucial 
factors have been overlooked which could have been important like promising 
biomarkers including novel imaging methodologies (specially fMRI), metabolomics, 
proteomics, electroencephalogram and even digital health platform technologies that 
will reduce the time for validation and encourage data integration across studies. Peer-
reviewed publications were identified through search in PubMed, Google scholar and 
SCI-HUB by using the search terms "fMRI", "Alzheimer", "cognitive side effects", 
"drug", "pharmacological neuroimaging". The search was limited to articles published 
in English. Relevant articles were chosen based on clinical experiences and the expertise 
of the authors. 
Conclusion: 
FMRI measures hold promise for multiple clinical applications. Generally, models 
especially pharmacological fMRI showed that drug repositioning is a cost-effective way 
to develop disease-modifying treatments over shorter timescale and future models 
should provide a theory of how increasing Ach levels using cholinesterase inhibitors 
and N-methyl-d-aspartate antagonists (NMDA)   impact neural and behavioral processes 
in AD. Models should also investigate how memantine (NMDA antagonists) can reduce 
toxicity of beta-amyloids as reported in experimental studies. 
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